(3-30 mg/kg; p.o. twice daily for 14 d) decreases Bleomycin-induced collagen deposition/lung fibrosis in rats . Pharmacokinetics of BMS-986278 in preclinical species plasma clearance ((mL/min)/kg) V ss (L/kg) oral bioavailability (%) T 1/2 (h) plasma protein binding (% free) ...
Table 9. Pharmacokinetic Profiles of33in Preclinical Species (Mouse, Rat, and Monkey) a aMouse PK, CD-1 mice (n= 4); rat PK, Sprague-Dawley rats (n= 3); monkey PK, cynomolgus monkeys (n= 2). for all 3...
BMS-986278 demonstrates excellent pharmacokinetics in preclinical species: 1) oral bioavailability = 70% (mouse); 100% (rat); 79% (monkey) and 2) clearance (mL/min/kg) = 37 (mouse); 15 (rat); 2 (monkey). BMS-986278 has negligible activity at bile acid and other clinically relevant ...